Celltrion Healthcare launches 'Ramshima SC' in the Netherlands
Corona 19 also accelerates market expansion
-Launched 'Ramshima SC' in the Netherlands on the 27th of last month.
-In the first week of launch, a request was made to purchase 'Ramshima SC' directly from a Dutch hospital ... Interested by local medical staff ?
-Signed a contract with CZ, the largest private insurance company in the Netherlands
[2020-05-07] Celltrion Healthcare expands and markets European sales of 'Rimshima SC' (a component name: Infliximab), a subcutaneous injection-type biopharmaceutical for the treatment of autoimmune diseases despite Corona 19 (COVID-19) We continue to strengthen our activities.
Celltrion Healthcare launched 'Ramshima SC' in the Netherlands on the 27th (local time) following Germany and the UK.?The company held the 'Ramshima SC launching symposium' on the 21st to successfully expand the 'Lamshima SC' market in the Netherlands.?The event was held online to prevent corona19 virus infection, and over 200 key medical personnel such as doctors, pharmacists, and hospital medicine purchasing managers participated to show high expectations for 'Ramshima SC'.
Head of Rheumatology Department, Tom Huizinga, Leiden University, Netherlands, who participated as a presenter, said, "Clinical results 'Ramshima SC' has similar results in effectiveness and safety compared to the existing IV type (intravenous injection). "The Ramsima SC has the strength of dual formulations that can be used for treatment with the IV formulation" Ramsima ". "We will be able to selectively treat depending on the condition."?
Medical staff who participated in the launching event also responded favorably to the transition from Infliximab IV type to 'Ramshima SC' and expected that 'Ramshima SC' would be a safe and effective treatment plan.?
Along with this, CZ, one of the largest private insurance companies in the Netherlands, decided to reimburse the entire treatment fee for 'Ramshima SC'.?CZ said that 'Ramshima SC' allows many patients to administer infliximab directly at home, which can be an effective treatment for patients as it minimizes hospital visits, especially in Corona19 situations.?In addition, CZ's SC formulation is usually more expensive than IV formulation, but 'Ramshima SC' is expected to be a good alternative to the infliximab formulation.?
An official from Celltrion Healthcare said, "The launch of 'Ramshima SC' is proceeding smoothly as originally planned despite the spread of Corona 19." "The response is positive enough to request a direct purchase from a local hospital in the Netherlands in the first week, so we will do our best to help patients continue their treatment safely and effectively through" Ramshima SC. "?
<Above>
? Attach pictures
? Presenters having a conversation at the 'Lamshima SC launching symposium' held online in the Netherlands on April 21 (from the left, head of the Department of Rheumatology, Jaap Van Laar, Utrecht University Hospital, Netherlands) (Inge Diepman) Medical journalist, Head of rheumatology at Tom Huizinga, Leiden University, member of the board of directors of the Dutch biosimilar and Anton Franken, physician of the Isala Zwolle Hospital / Photo credit: Celltrion Healthcare
